Milla RUNSALA | Business Development Manager
DelSiTech Ltd
Dr. Milla Runsala earned her Doctorate from the University of Turku, where she researched immune responses. She currently serves as a Business Development Manager, focusing on exploring new opportunities for sustained drug therapies using Silica Matrix drug delivery technology. Recently, DelSiTech demonstrated that sustaining antigen release with Silica Matrix technology significantly enhances induced immune responses in HIV. Dr. Runsala is confident that DelSiTech’s slow-release Silica Matrix technology could revolutionize future vaccine therapies.
Appearances:
Day 2 - Wednesday 15th October @ 11:45
Preclinical Studies on a Single-Administration HIV mRNA and Protein Trimer Vaccine Utilizing Long-Acting Silica Matrix Technology
Session led by:
Day 2 - Wednesday 15th October @ 11:45
Preclinical Studies on a Single-Administration HIV mRNA and Protein Trimer Vaccine Utilizing Long-Acting Silica Matrix Technology
Session led by:
last published: 07/May/25 13:55 GMT
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events